Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC3T2S)

Drug Name

PIRODOMAST Drug Info

Synonyms

Sch-37224; Pirodomast; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidine; 1-(4-Hydroxy-2-oxo-1-phenyl-1,2-dihydro-1,8-naphthyridin-3-yl)pyrrolidinium hydroxide inner salt; 4-Hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-one

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 2	[1]

Cross-matching ID

PubChem CID: 54680204
CAS Number: CAS 108310-20-9
TTD Drug ID: DMC3T2S

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Leukotriene receptor (LTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SR-2640	DMFDA4Y	Asthma	CA23	Phase 2	[3]
Ontazolast	DMS8Q7A	Asthma	CA23	Phase 2	[4]
WF-11605	DM57FHW	Bacterial infection	1A00-1C4Z	Phase 1	[5]
SK&F-S-106203	DM2BDAW	Asthma	CA23	Discontinued in Phase 2	[6]
FK-664	DMFGJNW	Cardiac disease	BA00-BE2Z	Discontinued in Phase 2	[7]
SMP-028	DMQSGOD	Asthma	CA23	Discontinued in Phase 1	[8]
NZ-107	DMXJO5F	Asthma	CA23	Discontinued in Phase 1	[9]
ABT-080	DMTYWE9	Asthma	CA23	Discontinued in Phase 1	[10]
BAY-Y-1015	DM0UEKF	Inflammation	1A00-CA43.1	Discontinued in Phase 1	[11]
ICI-198615	DM0195G	Asthma	CA23	Terminated	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukotriene receptor (LTR)	TTTWGIX	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000038)
2	Antiallergy activity of Sch 37224, a new inhibitor of leukotriene formation. J Pharmacol Exp Ther. 1988 Dec;247(3):997-1003.
3	Effect of the leukotriene LTD4/LTE4 antagonist, SR 2640, in ulcerative colitis: an open clinical study. Prostaglandins Leukot Essent Fatty Acids. 1991 Mar;42(3):181-4.
4	Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance. Eur J Med Res. 1997 Apr 21;2(4):159-64.
5	WF11605, an antagonist of leukotriene B4 produced by a fungus. II. Structure determination. J Antibiot (Tokyo). 1992 May;45(5):704-8.
6	Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig. Pulm Pharmacol. 1991;4(3):177-89.
7	US patent application no. 7,175,854, Pharmaceutical preparation comprising an active dispersed on a matrix.
8	Effect of SMP-028 on steroidogenesis in rats; mechanism of toxicological events on endocrine organs of rats. Toxicol In Vitro. 2014 Apr;28(3):397-402.
9	Effects of NZ-107 on tracheal responses to adenosine in the guinea pig. Jpn J Pharmacol. 1991 May;56(1):79-84.
10	An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010 February; 10(1): 60-66.
11	The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum. 1996 Mar;39(3):515-21.
12	In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther. 1987 Nov;243(2):548-56.